In last trading session, Moderna Inc (NASDAQ:MRNA) saw 5.97 million shares changing hands with its beta currently measuring 1.82. Company’s recent per share price level of $32.06 trading at $0.48 or 1.52% at ring of the bell on the day assigns it a market valuation of $12.40B. That closing price of MRNA’s stock is at a discount of -296.76% from its 52-week high price of $127.20 and is indicating a premium of 27.79% from its 52-week low price of $23.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 10.96 million shares which gives us an average trading volume of 10.77 million if we extend that period to 3-months.
For Moderna Inc (MRNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.86. Splitting up the data highlights that, out of 17 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 12 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Moderna Inc (NASDAQ:MRNA) trade information
Upright in the green during last session for gaining 1.52%, in the last five days MRNA remained trading in the red while hitting it’s week-highest on Thursday, 07/10/25 when the stock touched $32.06 price level, adding 6.78% to its value on the day. Moderna Inc’s shares saw a change of -73.60% in year-to-date performance and have moved -2.23% in past 5-day. Moderna Inc (NASDAQ:MRNA) showed a performance of 20.21% in past 30-days. Number of shares sold short was 63.56 million shares which calculate 4.88 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 47.5 to the stock, which implies a rise of 32.51% to its current value. Analysts have been projecting 45 as a low price target for the stock while placing it at a high target of 50. It follows that stock’s current price would drop -40.36% in reaching the projected high whereas dropping to the targeted low would mean a loss of -40.36% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -42.94% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -9.63% while estimates for its earnings growth in next 5 years are of 20.19%.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Insiders are in possession of 7.28% of company’s total shares while institution are holding 73.67 percent of that, with stock having share float percentage of 79.45%. Investors also watch the number of corporate investors in a company very closely, which is 73.67% institutions for Moderna Inc that are currently holding shares of the company. BAILLIE GIFFORD & CO is the top institutional holder at MRNA for having 43.45 million shares of worth $5.16 billion. And as of 2024-06-30, it was holding 11.3149 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 39.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.3028 of outstanding shares, having a total worth of $4.7 billion.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 10.96 shares of worth $351.41 million or 2.83% of the total outstanding shares. The later fund manager was in possession of 9.41 shares on Mar 31, 2025 , making its stake of worth around $301.67 million in the company or a holder of 2.43% of company’s stock.
